Advaxis, Inc. (ADXS)
| Market Cap | 85.88M |
| Revenue (ttm) | 253,000 |
| Net Income (ttm) | -26.47M |
| Shares Out | 61.00M |
| EPS (ttm) | -0.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $0.767 |
| Previous Close | $0.830 |
| Change ($) | -0.063 |
| Change (%) | -7.58% |
| Day's Open | 0.832 |
| Day's Range | 0.745 - 0.835 |
| Day's Volume | 9,140,545 |
| 52-Week Range | 0.264 - 1.570 |
Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors
Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program
PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy produc...
New York, New York--(Newsfile Corp. - December 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Advaxis, Inc. (NASDAQ: ADXS) concerning possible breaches of fiduciar...
PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immu...
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and anal...
Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluri...
PRINCETON, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immu...
PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immu...
Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA ®
PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis , Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy produ...
PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy pro...
Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND
Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors
PRINCETON, N.J., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy pro...
PRINCETON, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy prod...
PRINCETON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy prod...
PRINCETON, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy prod...
Advaxis, Inc. (ADXS) CEO Ken Berlin on Q2 2020 Results - Earnings Call Transcript
Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update
Expanding Phase 1/2 Study of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two patients from Part B combination arm with KEYTRUDA®
Sustained clinical benefit seen in patients treated with ADXS-503 in combination with KEYTRUDA® after 16 weeks, including a partial response and stable disease in patients who had most recentl...
Advaxis Is One Biotech That Should Be On Your Radar; Targeting Large NSCLC And Prostate Cancer Drug Markets
First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA®
PRINCETON, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of im...
Advaxis, Inc. (ADXS) CEO Kenneth Berlin on Q2 2019 Results - Earnings Call Transcript
Nanocap Advaxis, Inc. is seeing strength Wednesday following an announcement concerning its cervical cancer drug.
Advaxis (ADXS) closed the most recent trading day at $3.29, moving -0.3% from the previous trading session.
Is (ADXS) Outperforming Other Medical Stocks This Year?
Here's a roundup of top developments in the biotech space over the last 24 hours.
Shares of Advaxis Inc. plummeted 25% to pace all premarket declines Wednesday, after the biotechnology company's public offering of shares priced at a deep discount.
The small-cap biotech reported encouraging news about its prostate cancer therapy.
Advaxis, Inc. has announced a reverse stock split and clinical trial updates at the American Association of Cancer Research annual meeting in recent days.
As of late, it has definitely been a great time to be an investor in Advaxis.
This owner and operator of a late-stage biotechnology company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 64.7% over th...
Is (ADXS) Outperforming Other Medical Stocks This Year?
About ADXS
Advaxis, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies... [Read more...]
| Industry Biotechnology | Founded 2002 |
| CEO Kenneth Berlin | Employees 17 |
| Stock Exchange NASDAQ | Ticker Symbol ADXS |
Financial Performance
In 2020, Advaxis's revenue was $253,000, a decrease of -98.79% compared to the previous year's $20.88 million. Losses were -$26.47 million, 59.3% more than in 2019.